Brief: Evaxion Announces Promising Clinical Data For DNA-Based Personalized Cancer Immunotherapy

Evaxion A/S

18/04/2023 13:03

April 18 (Reuters) - Evaxion Biotech A/S  EVAX.O :
    * EVAXION ANNOUNCES PROMISING CLINICAL DATA FOR DNA-BASED
PERSONALIZED CANCER IMMUNOTHERAPY EVX-02: PHASE 1/2A TRIAL MET
BOTH PRIMARY AND SECONDARY ENDPOINTS
    * EVAXION BIOTECH: ALL 10 PATIENTS WITH LATE STAGE MELANOMA
WHO
COMPLETED EVX-02 TREATMENT DEMONSTRATED ROBUST AND
TREATMENT-SPECIFIC IMMUNE RESPONSES
    * EVAXION BIOTECH A/S: ALL 10 PATIENTS WERE RELAPSE-FREE AT
THEIR
LAST ASSESSMENT
    * EVAXION BIOTECH A/S: ROBUST AND LONG-LASTING
NEOANTIGEN-SPECIFIC
T-CELL IMMUNE RESPONSES WERE CONFIRMED IN ALL EVX-02 COMPLETERS
    * EVAXION BIOTECH A/S: COMBINATION OF EVX-02 AND NIVOLUMAB
WAS
WELL TOLERATED AND ONLY MILD EVX-02-ASSOCIATED AES WERE OBSERVED
    * EVAXION BIOTECH: ONE PATIENT PREMATURELY TERMINATED DUE TO
NON-EVX-02 RELATED ADVERSE EVENTS (AES), AND WAS RELAPSE-FREE AT
LAST VISIT AT 9 MONTHS
    * EVAXION BIOTECH A/S - STUDY, IN PATIENTS WITH RESECTED
MELANOMA,
SHOWED THAT INDUCED T-CELL IMMUNE RESPONSES INVOLVED BOTH CD4+
AND CD8+ T CELLS
    * EVAXION BIOTECH A/S: RESULTS SUPPORT OUR PLAN TO FAST
TRACK OUR
NEXT-GENERATION DNA-BASED PERSONALIZED CANCER IMMUNOTHERAPY,
EVX-03, TO CLINIC IN Q4

Source text for Eikon:  ID:nGNX9F8YcT 
Further company coverage:  EVAX.O